Strata Oncology's mission is to transform cancer care through large-scale molecularly-informed clinical research. 



Strata for Health Systems


Advanced Clinical Research and Care for the Precision Oncology Era

Our precision oncology platform provides a comprehensive, streamlined solution centered on a systematic, rather than individual physician-led, approach to deliver a new, precision oncology standard of care. By deploying a clinical research-driven model for precision oncology that supports enterprise-wide access and continuous learning, our partners are leading the way in cancer clinical research and care.



Strata for Biopharma

Cancer Drug Development
for the Precision Oncology Era

We offer biopharmaceutical partners the most efficient path to new and expanded precision drug approvals. Our pioneering approach includes access to a network of trial ready sites and the largest clinical-genomic database of trial candidates, potentially eligible for immediate enrollment, to provide an unprecedented ability to learn from real-world data and rapidly translate insights to active prospective studies.


Strata Precision Oncology Network

The leading network for investigators and biopharma to design and conduct potentially
transformative precision cancer therapy studies.



In the News


CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101,
a c-Met inhibitor, for Patients with
Non-Small Cell Lung Cancer and other Solid Tumors 

The companies have entered into an agreement to drive patient enrollment in CBT’s ongoing Phase 1/2 trial of CBT-101 in cancer patients with c-Met dysregulated malignancies including non-small cell lung cancer…

Read more.


Merck, Pfizer power tumor profiling firm Strata to $26M round

The VC wings of Merck and Pfizer have led a $26 million series B investment in Strata Oncology. Raising the cash sets Strata up to... Read more.